The European Medicines Agency (EMA) will begin a study next week on the efficacy and safety of the Russian vaccine Covid-19 “Sputnik-V”. The information is published by the British publication “Financial Times”, which is based on the words of the official representative of the Kremlin, Kirill Dimitriev.
The newspaper also published statements by several anonymous representatives of the EU regulator, who expressed concern about the ethical side of the Russian vaccine review. Kirill Dmitriev even says that “pressure on the regulator of the bloc [ვაქცინის განხილვის მიზნით] “It did not take place and Sputnik-V is preparing to fight Kovid-19 in Russia and around the world.”
Russia is now aggressively advertising its own vaccine. If the European Medicines Agency approved the Russian vaccine, it indicates that in clinical trials, Russian scientists, during the testing of the vaccine, followed the so-called. International Standards for Good Clinical Practice (GCP).
EU officials said a few weeks ago that neither consideration nor approval meant that the bloc would be bought by Sputnik. However, if the EU regulator considers it effective and safe, it will undoubtedly increase the reputation of the Russian vaccine in the international market.
On the other hand, the Russian vaccine was purchased and used by several EU countries before being approved in Europe. These are: Hungary, Slovakia and Northern Macedonia.